S&P 500   4,575.36 (+0.01%)
DOW   35,655.20 (-0.28%)
QQQ   381.28 (+0.57%)
AAPL   149.08 (-0.16%)
MSFT   322.16 (+3.89%)
FB   314.10 (-0.54%)
GOOGL   2,928.99 (+5.13%)
TSLA   1,054.40 (+3.53%)
AMZN   3,385.85 (+0.29%)
NVDA   248.55 (+0.56%)
BABA   168.50 (-0.88%)
NIO   39.80 (-1.66%)
CGC   13.00 (-1.29%)
GE   103.97 (-3.23%)
AMD   125.35 (+1.97%)
MU   68.37 (-0.83%)
T   25.19 (-0.71%)
F   15.75 (-1.19%)
ACB   6.94 (-1.28%)
DIS   169.68 (-1.37%)
PFE   42.87 (-1.58%)
BA   206.79 (-1.44%)
AMC   35.39 (-1.83%)
S&P 500   4,575.36 (+0.01%)
DOW   35,655.20 (-0.28%)
QQQ   381.28 (+0.57%)
AAPL   149.08 (-0.16%)
MSFT   322.16 (+3.89%)
FB   314.10 (-0.54%)
GOOGL   2,928.99 (+5.13%)
TSLA   1,054.40 (+3.53%)
AMZN   3,385.85 (+0.29%)
NVDA   248.55 (+0.56%)
BABA   168.50 (-0.88%)
NIO   39.80 (-1.66%)
CGC   13.00 (-1.29%)
GE   103.97 (-3.23%)
AMD   125.35 (+1.97%)
MU   68.37 (-0.83%)
T   25.19 (-0.71%)
F   15.75 (-1.19%)
ACB   6.94 (-1.28%)
DIS   169.68 (-1.37%)
PFE   42.87 (-1.58%)
BA   206.79 (-1.44%)
AMC   35.39 (-1.83%)
S&P 500   4,575.36 (+0.01%)
DOW   35,655.20 (-0.28%)
QQQ   381.28 (+0.57%)
AAPL   149.08 (-0.16%)
MSFT   322.16 (+3.89%)
FB   314.10 (-0.54%)
GOOGL   2,928.99 (+5.13%)
TSLA   1,054.40 (+3.53%)
AMZN   3,385.85 (+0.29%)
NVDA   248.55 (+0.56%)
BABA   168.50 (-0.88%)
NIO   39.80 (-1.66%)
CGC   13.00 (-1.29%)
GE   103.97 (-3.23%)
AMD   125.35 (+1.97%)
MU   68.37 (-0.83%)
T   25.19 (-0.71%)
F   15.75 (-1.19%)
ACB   6.94 (-1.28%)
DIS   169.68 (-1.37%)
PFE   42.87 (-1.58%)
BA   206.79 (-1.44%)
AMC   35.39 (-1.83%)
S&P 500   4,575.36 (+0.01%)
DOW   35,655.20 (-0.28%)
QQQ   381.28 (+0.57%)
AAPL   149.08 (-0.16%)
MSFT   322.16 (+3.89%)
FB   314.10 (-0.54%)
GOOGL   2,928.99 (+5.13%)
TSLA   1,054.40 (+3.53%)
AMZN   3,385.85 (+0.29%)
NVDA   248.55 (+0.56%)
BABA   168.50 (-0.88%)
NIO   39.80 (-1.66%)
CGC   13.00 (-1.29%)
GE   103.97 (-3.23%)
AMD   125.35 (+1.97%)
MU   68.37 (-0.83%)
T   25.19 (-0.71%)
F   15.75 (-1.19%)
ACB   6.94 (-1.28%)
DIS   169.68 (-1.37%)
PFE   42.87 (-1.58%)
BA   206.79 (-1.44%)
AMC   35.39 (-1.83%)
NASDAQ:OPTN

OptiNose Stock Forecast, Price & News

$2.70
-0.05 (-1.82 %)
(As of 10/27/2021 11:48 AM ET)
Add
Compare
Today's Range
$2.67
$2.78
50-Day Range
$2.35
$3.16
52-Week Range
$2.32
$5.11
Volume832 shs
Average Volume354,706 shs
Market Capitalization$143.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.99
30 days | 90 days | 365 days | Advanced Chart
Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.


OptiNose logo

About OptiNose

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPTN
Employees
206
Year Founded
N/A

Sales & Book Value

Annual Sales
$49.12 million
Book Value
$0.13 per share

Profitability

Net Income
$-99.79 million
Net Margins
-152.39%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$143.93 million
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.01 out of 5 stars

Medical Sector

570th out of 1,363 stocks

Pharmaceutical Preparations Industry

270th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












OptiNose (NASDAQ:OPTN) Frequently Asked Questions

Is OptiNose a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose
or view top-rated stocks.

What stocks does MarketBeat like better than OptiNose?

Wall Street analysts have given OptiNose a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OptiNose wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OptiNose's next earnings date?

OptiNose is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for OptiNose
.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) posted its earnings results on Wednesday, August, 11th. The company reported ($0.44) EPS for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.02. The firm earned $18.36 million during the quarter, compared to analysts' expectations of $17.35 million. OptiNose had a negative trailing twelve-month return on equity of 1,275.55% and a negative net margin of 152.39%.
View OptiNose's earnings history
.

How has OptiNose's stock price been impacted by Coronavirus (COVID-19)?

OptiNose's stock was trading at $5.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPTN stock has decreased by 47.2% and is now trading at $2.67.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OPTN?

1 equities research analysts have issued twelve-month price targets for OptiNose's shares. Their forecasts range from $10.00 to $12.00. On average, they anticipate OptiNose's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 312.0% from the stock's current price.
View analysts' price targets for OptiNose
or view top-rated stocks among Wall Street analysts.

Who are OptiNose's key executives?

OptiNose's management team includes the following people:
  • Peter Kaighn Miller, Chief Executive Officer & Director
  • Ramy A. Mahmoud, President & Chief Operating Officer (LinkedIn Profile)
  • Keith Alan Goldan, Chief Financial Officer
  • John C. Messina, SVP-Clinical Development & Medical Affairs
  • Michael C. Berkey, Vice President-Technical Operations

What other stocks do shareholders of OptiNose own?

When did OptiNose IPO?

(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $2.67.

How much money does OptiNose make?

OptiNose has a market capitalization of $142.34 million and generates $49.12 million in revenue each year. The company earns $-99.79 million in net income (profit) each year or ($2.07) on an earnings per share basis.

How many employees does OptiNose have?

OptiNose employs 206 workers across the globe.

What is OptiNose's official website?

The official website for OptiNose is www.optinose.com.

Where are OptiNose's headquarters?

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at (267) 364-3500 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.